G-dase E for HPV+ OPSCC
HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC)
Pre-clinicalActive
Key Facts
Indication
HPV-induced Oropharyngeal Head & Neck Cancer (OPSCC)
Phase
Pre-clinical
Status
Active
Company
About Akribion Therapeutics
Akribion Therapeutics is an early-stage, Munich-based biotech that exited stealth in February 2025 with an €8 million seed financing round. The company is developing a unique platform technology centered on G-dase® E, a programmable cytotoxic nuclease that depletes cells with single-nucleotide specificity guided by RNA sequences. This approach, initially targeting HPV+ head and neck cancer, has broad potential applications across oncology, autoimmune diseases, fibrosis, and infectious diseases. The company is led by an experienced team with roots in BRAIN Biotech AG, where the core technology was discovered.
View full company profile